An interventional study of 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution and 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution in Open-angle Glaucoma and Ocular Hypertension, sponsored by Allergan. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2019-04-17.
Sponsored by Allergan (part of AbbVie) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies testing bimatoprost in Glaucoma, Open-Angle — 2 open to participants now, 2 under way, 1 of them phase 3. Bimatoprost · Glaucoma, Open-Angle.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, this one is the 12th largest by enrollment, is one of 5 that started in 2010, is the only one with no phase, and was the 2nd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 29 studies testing bimatoprost in Glaucoma, Open-Angle are open now, in 2 countries. Recruiting first, the newest first:
YS Life Science Co., Ltd. · Sites in United States, India
Ages 18+
Amneal Pharmaceuticals, LLC · Sites in United States
Ages 18+
By country, each count listing its studies:
Bimatoprost: first FDA approval 2001 (LUMIGAN), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →
Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 9 · Phase 4 12
First in 2007; this study’s year is marked. 5 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 235 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 169 across the 29 interventional studies. Of the 27 that completed or were terminated, 23 (85%) have results posted.
This tab as a report to print or save as PDF → With an account.
28 of 29 have an industry lead sponsor. The 7 most frequent:
This study is registered under Allergan, one of the names counted as AbbVie. Under that name alone:
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
58 studies in Glaucoma, Open-Angle by AbbVie: 1 open now, 3 under way, 1 of them phase 3. Of 54 finished, 42 (78%) have results posted.
Among the 58 studies in Glaucoma, Open-Angle by AbbVie, this one is the 13th largest by enrollment of the 34 interventional ones that give a count, is one of 12 that started in 2010, is the only one with no phase, and was the 10th registered.
AbbVie’s Glaucoma, Open-Angle studies by the year they started, since 1999.
1 of the studies testing bimatoprost in Glaucoma, Open-Angle that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07661329Phase 3YS Life Science Co., Ltd.A Study to Evaluate Efficacy and Safety of YSBP Compared to Lumigan in Patients With Glaucoma or Ocular Hypertension | 2027-11-01 |
Add it to your calendar (.ics) → With an account.
Among the 29 studies testing bimatoprost in Glaucoma, Open-Angle, from their registry updates:
Among AbbVie’s 58 in Glaucoma, Open-Angle:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the safety and efficacy of once daily administered 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution compared with once daily administered 0.03% Bimatoprost Ophthalmic Solution and once daily administered 0.5% Timolol Ophthalmic Solution concurrently in patients with open-angle glaucoma or ocular hypertension
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
Drug: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution
Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
Drug: 0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution
Drug pages: Bimatoprost · Timolol
One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
Also known as: Bottle 1: Ganfort®
Drug pages: Bimatoprost Ophthalmic Solution · Timolol
One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
Also known as: Bottle 1: Lumigan®, Bottle 2: Timoptol®
The Difference of Change From Baseline of Mean Diurnal Intraocular Pressure (IOP) Between the Two Treatment Groups at Week 4
The difference of change from baseline of mean diurnal IOP between the 0.03% Bimatoprost/0.5% Timolol in Same Bottle and the 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles at week 4. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of the study eye (the eye with the highest IOP at baseline) over the 3 time points measured at 8AM, 12PM and 4PM. A negative number change from baseline indicated a reduction (improvement) in IOP. The difference of change from baseline in IOP is presented in the statistical analysis section.
Time frame: Baseline, Week 4
| Milestone | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles |
|---|---|---|
| Started | 121 | 114 |
| Completed | 113 | 104 |
| Not completed | 8 | 10 |
The difference of change from baseline of mean diurnal IOP between the 0.03% Bimatoprost/0.5% Timolol in Same Bottle and the 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles at week 4. IOP is a measurement of the fluid pressure inside the eye. Mean diurnal IOP is the average of the IOP values of the study eye (the eye with the highest IOP at baseline) over the 3 time points measured at 8AM, 12PM and 4PM. A negative number change from baseline indicated a reduction (improvement) in IOP. The difference of change from baseline in IOP is presented in the statistical analysis section.
| Millimeters of mercury (mmHg) | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles |
|---|---|---|
| Baseline | 25.20 ± 3.06 | 24.87 ± 3.88 |
| Change from Baseline at Week 4 | -9.38 ± 4.66 | -8.93 ± 4.25 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.03% Bimatoprost/0.5% Timolol in Same Bottle | — | 0/121 (0%) | 30/121 (24.8%) |
| 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles | — | 2/114 (1.8%) | 29/114 (25.4%) |
| Event | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles |
|---|---|---|
| GoitreEndocrine disorders | 0/121 | 1/114 |
| Ocular hypertensionEye disorders | 0/121 | 1/114 |
| Event | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles |
|---|---|---|
| Conjunctival hyperaemiaEye disorders | 26/121 | 21/114 |
| Eye painEye disorders | 4/121 | 8/114 |
| Age, Continuous(years) | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles | Total |
|---|---|---|---|
| Mean | 45.73 ± 14.77 | 44.28 ± 16.28 | 45.02 ± 15.51 |
| Sex: Female, Male(Participants) | 0.03% Bimatoprost/0.5% Timolol in Same Bottle | 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles | Total |
|---|---|---|---|
| Female | 46 | 46 | 92 |
| Male | 75 | 68 | 143 |
Ran from Feb 2010 to primary completion in Sep 2010, 7 months.
Results were first posted in Jan 2012, 1 year 4 months after primary completion.
Of 70 industry-sponsored interventional studies with no phase under Glaucoma, Open-Angle, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 64. This study's 7 months is below that.
Counting every sponsor, half of 171 studies reached it within 35 months; a quarter within 19 and three quarters within 61.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Bimatoprost · Timolol